NVCR Stock: Price, Earnings History and SEC Filings
NovoCure Limited (NVCR) last traded at $13.15, up 0.31% on the latest session and down 17.6% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-0.09 against an analyst estimate of $-0.21, a beat of 57.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NVCR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-0.09 | $-0.21 | +57.14% |
| Jun 2026 | Jul 23, 2026 | $-0.13 | $-0.30 | +56.67% |
| Mar 2026 | Apr 30, 2026 | $-0.62 | $-0.40 | -55.00% |
| Dec 2025 | Feb 26, 2026 | $-0.22 | $-0.41 | +46.34% |
NVCR beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How NVCR reacts to earnings
Across its last 8 earnings releases, NVCR moved 13.3% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | Before open | -7.48% |
| 2026-07-23 | Before open | +28.39% |
| 2026-04-30 | Before open | +27.49% |
| 2026-02-26 | Before open | -8.27% |
| 2026-01-12 | Before open | -1.18% |
| 2025-10-30 | Before open | -4.90% |
| 2025-07-24 | Before open | -24.05% |
| 2025-04-24 | Before open | +4.39% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
NVCR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $655M | -$136M | -$76M | -20.8% | $-1.22 |
| 2024 | $605M | -$169M | -$69M | -27.9% | $-1.56 |
| 2023 | $509M | -$207M | -$100M | -40.6% | $-1.95 |
| 2022 | $538M | -$93M | $9M | -17.2% | $-0.88 |
| 2021 | $535M | -$58M | $59M | -10.9% | $-0.56 |
| 2020 | $494M | $20M | $84M | 4.0% | $0.18 |
| 2019 | $351M | -$7M | $16M | -2.1% | $-0.07 |
| 2018 | $248M | -$64M | -$9M | -25.6% | $-0.69 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for NVCR
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 10-Q · Oct 29, 2026
- 8-K · Oct 1, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 9, 2026Officer or director change, Financial statements and exhibits
- 8-K · Sep 1, 2026Other events, Financial statements and exhibits
- 8-K · Jul 23, 2026Results of operations, Financial statements and exhibits
- 10-Q · Jul 23, 2026
- 8-K · Jun 30, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 18, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 5, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
Insider filing activity
NVCR insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NVCR news
- NovoCure (NVCR) Q3 Results Spark Margin Turn DebateOct 31, 2026 · finance.yahoo.com
- NovoCure Stock Is In Focus After Earnings Beat And Slower Optune Pax LaunchOct 30, 2026 · finance.yahoo.com
- NovoCure Q3 Earnings Call HighlightsOct 29, 2026 · marketbeat.com
- NovoCure (NVCR) Q3 2026 Earnings Call TranscriptOct 29, 2026 · fool.com
- Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct CompetitionOct 29, 2026 · stocktwits.com
- NovoCure Sinks 5% Despite Guidance Raise as Pancreatic Cancer Launch Access Is “Significantly Limited”Oct 29, 2026 · tikr.com
- NovoCure (NVCR) Reports Q3 Loss, Tops Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- NovoCure: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
About NovoCure Limited
NovoCure Limited (NVCR) is a US-listed public company on Nasdaq. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. Its fiscal year ends in December.